Premium
Oropharyngeal carriage of Candida species in HIV‐infected patients in India
Author(s) -
Gugnani H. C.,
Becker K.,
Fegeler W.,
Basu S.,
Chattopadhya D.,
Baveja U.,
Satyanarayana S.,
Kalghatgi T.,
Murlidhar A.
Publication year - 2003
Publication title -
mycoses
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.13
H-Index - 69
eISSN - 1439-0507
pISSN - 0933-7407
DOI - 10.1046/j.1439-0507.2003.00896.x
Subject(s) - flucytosine , itraconazole , fluconazole , voriconazole , microbiology and biotechnology , amphotericin b , candida albicans , miconazole , candida dubliniensis , biology , azole , medicine , corpus albicans , virology , antifungal
Summary The present investigation represents the first study of oropharyngeal carriage of Candida and other yeasts in HIV‐infected patients in India. One hundred and fifty HIV‐positive patients were investigated by culturing their swish samples on plates of CHROMagar Candida . Ninety‐eight patients (65.3%) were positive for Candida and four (2.7%) were positive for other yeasts. Among them, the first Indian C. dubliniensis isolate has been recovered. Molecular typing of selected C. albicans isolates by AP‐PCR revealed two major genotypes based on the banding patterns. The susceptibilities of 30 Candida isolates to five antifungal agents including the new triazole voriconazole were determined in a micro‐dilution test, according to the NCCLS protocol M 27. All the 22 C. albicans isolates were susceptible to five antimycotic agents (flucytosine, amphotericin B, fluconazole, voriconazole and itraconazole) except one isolate (VPCI‐122), which was resistant to flucytosine (MIC ≥ 64 mg l −1 ). The azole‐resistant isolates reported here endorse the role of antifungal susceptibility testing whenever antifungal treatment with azoles is planned.